Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
Highlights • 3rd generation EGFR TKIs are T790M selective with minimal inhibition in WT EGFR. • The 3rd generation EGFR TKIs are highly active and are well tolerated. • Acquired resistance to 3rd generation EGFR TKIs include EGFR C797S mutation. • A new class of EGFR TKI has increased CNS penetratio...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-03, Vol.93, p.59-68 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 68 |
|---|---|
| container_issue | |
| container_start_page | 59 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 93 |
| creator | Tan, Chee-Seng Cho, Byoung-Chul Soo, Ross A |
| description | Highlights • 3rd generation EGFR TKIs are T790M selective with minimal inhibition in WT EGFR. • The 3rd generation EGFR TKIs are highly active and are well tolerated. • Acquired resistance to 3rd generation EGFR TKIs include EGFR C797S mutation. • A new class of EGFR TKI has increased CNS penetration with promising CNS activity. |
| doi_str_mv | 10.1016/j.lungcan.2016.01.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1767623102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0169500216300034</els_id><sourcerecordid>1767623102</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-b4dc3e6944ae7a7d455ec195ba5f2e69902fe01fe40469d11b47bbd61d19b9883</originalsourceid><addsrcrecordid>eNqFUk1v1DAQtRCILoWfAMqRS4LHSZz4AkJVC0hVOQBny3EmW28TZ7Edyv6N_mIm2oUDl178Ne_N-M0bxl4DL4CDfLcrxsVvrfGFoGvBoeC8fMI20DYib8tSPGUbCqi85lycsRcx7jiHBrh6zs6EbFUrQW7Yww3-TvkWPQaT3Owz3Lsew2TGbBvm-3SbDcamOWQBLe7XQzqEOTqP2Z3zJmLm_K3rHEUiHR-n59OSjE-Zn30eCTdmFmlZxWSkxmJ4yZ4NZoz46rSfsx9Xl98vPufXXz99ufh4nduqlSnvqt6WKFVVGWxM01d1jRZU3Zl6EPSuuBiQw4AVr6TqAbqq6bpeQg-qU21bnrO3x7z7MP9cMCY9ubh-xnicl6ihkY0UJXBB0PoItaQ9Bhz0PrjJhIMGrlc79E6f7NCrHZqDJjuI9-ZUYukm7P-x_vafAB-OACShvxwGHa1D6kLvqGNJ97N7tMT7_zLY0XlnzXiHB4y7eQmeuqhBR6G5_rbOxDoSVJwTvyr_AKUAtys</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1767623102</pqid></control><display><type>article</type><title>Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tan, Chee-Seng ; Cho, Byoung-Chul ; Soo, Ross A</creator><creatorcontrib>Tan, Chee-Seng ; Cho, Byoung-Chul ; Soo, Ross A</creatorcontrib><description>Highlights • 3rd generation EGFR TKIs are T790M selective with minimal inhibition in WT EGFR. • The 3rd generation EGFR TKIs are highly active and are well tolerated. • Acquired resistance to 3rd generation EGFR TKIs include EGFR C797S mutation. • A new class of EGFR TKI has increased CNS penetration with promising CNS activity.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2016.01.003</identifier><identifier>PMID: 26898616</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Blood-Brain Barrier - drug effects ; Blood-Brain Barrier - metabolism ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Clinical Trials as Topic ; Drug Discovery ; Drug Evaluation, Preclinical ; Epidermal growth factor receptor mutations ; Hematology, Oncology and Palliative Medicine ; HM61713 ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Molecular Targeted Therapy ; Mutation ; Non-small cell lung cancer ; Osimertinib ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Pulmonary/Respiratory ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - genetics ; Rociletinib ; Treatment Outcome ; Tyrosine kinase inhibitor</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2016-03, Vol.93, p.59-68</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2016 Elsevier Ireland Ltd</rights><rights>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-b4dc3e6944ae7a7d455ec195ba5f2e69902fe01fe40469d11b47bbd61d19b9883</citedby><cites>FETCH-LOGICAL-c486t-b4dc3e6944ae7a7d455ec195ba5f2e69902fe01fe40469d11b47bbd61d19b9883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0169500216300034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26898616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tan, Chee-Seng</creatorcontrib><creatorcontrib>Cho, Byoung-Chul</creatorcontrib><creatorcontrib>Soo, Ross A</creatorcontrib><title>Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Highlights • 3rd generation EGFR TKIs are T790M selective with minimal inhibition in WT EGFR. • The 3rd generation EGFR TKIs are highly active and are well tolerated. • Acquired resistance to 3rd generation EGFR TKIs include EGFR C797S mutation. • A new class of EGFR TKI has increased CNS penetration with promising CNS activity.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Blood-Brain Barrier - drug effects</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Clinical Trials as Topic</subject><subject>Drug Discovery</subject><subject>Drug Evaluation, Preclinical</subject><subject>Epidermal growth factor receptor mutations</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>HM61713</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Molecular Targeted Therapy</subject><subject>Mutation</subject><subject>Non-small cell lung cancer</subject><subject>Osimertinib</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pulmonary/Respiratory</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Rociletinib</subject><subject>Treatment Outcome</subject><subject>Tyrosine kinase inhibitor</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk1v1DAQtRCILoWfAMqRS4LHSZz4AkJVC0hVOQBny3EmW28TZ7Edyv6N_mIm2oUDl178Ne_N-M0bxl4DL4CDfLcrxsVvrfGFoGvBoeC8fMI20DYib8tSPGUbCqi85lycsRcx7jiHBrh6zs6EbFUrQW7Yww3-TvkWPQaT3Owz3Lsew2TGbBvm-3SbDcamOWQBLe7XQzqEOTqP2Z3zJmLm_K3rHEUiHR-n59OSjE-Zn30eCTdmFmlZxWSkxmJ4yZ4NZoz46rSfsx9Xl98vPufXXz99ufh4nduqlSnvqt6WKFVVGWxM01d1jRZU3Zl6EPSuuBiQw4AVr6TqAbqq6bpeQg-qU21bnrO3x7z7MP9cMCY9ubh-xnicl6ihkY0UJXBB0PoItaQ9Bhz0PrjJhIMGrlc79E6f7NCrHZqDJjuI9-ZUYukm7P-x_vafAB-OACShvxwGHa1D6kLvqGNJ97N7tMT7_zLY0XlnzXiHB4y7eQmeuqhBR6G5_rbOxDoSVJwTvyr_AKUAtys</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Tan, Chee-Seng</creator><creator>Cho, Byoung-Chul</creator><creator>Soo, Ross A</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160301</creationdate><title>Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer</title><author>Tan, Chee-Seng ; Cho, Byoung-Chul ; Soo, Ross A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-b4dc3e6944ae7a7d455ec195ba5f2e69902fe01fe40469d11b47bbd61d19b9883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Blood-Brain Barrier - drug effects</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Clinical Trials as Topic</topic><topic>Drug Discovery</topic><topic>Drug Evaluation, Preclinical</topic><topic>Epidermal growth factor receptor mutations</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>HM61713</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Molecular Targeted Therapy</topic><topic>Mutation</topic><topic>Non-small cell lung cancer</topic><topic>Osimertinib</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pulmonary/Respiratory</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Rociletinib</topic><topic>Treatment Outcome</topic><topic>Tyrosine kinase inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tan, Chee-Seng</creatorcontrib><creatorcontrib>Cho, Byoung-Chul</creatorcontrib><creatorcontrib>Soo, Ross A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tan, Chee-Seng</au><au>Cho, Byoung-Chul</au><au>Soo, Ross A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>93</volume><spage>59</spage><epage>68</epage><pages>59-68</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>Highlights • 3rd generation EGFR TKIs are T790M selective with minimal inhibition in WT EGFR. • The 3rd generation EGFR TKIs are highly active and are well tolerated. • Acquired resistance to 3rd generation EGFR TKIs include EGFR C797S mutation. • A new class of EGFR TKI has increased CNS penetration with promising CNS activity.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>26898616</pmid><doi>10.1016/j.lungcan.2016.01.003</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2016-03, Vol.93, p.59-68 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1767623102 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Blood-Brain Barrier - drug effects Blood-Brain Barrier - metabolism Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Clinical Trials as Topic Drug Discovery Drug Evaluation, Preclinical Epidermal growth factor receptor mutations Hematology, Oncology and Palliative Medicine HM61713 Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Molecular Targeted Therapy Mutation Non-small cell lung cancer Osimertinib Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Rociletinib Treatment Outcome Tyrosine kinase inhibitor |
| title | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T11%3A35%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Next-generation%20epidermal%20growth%20factor%20receptor%20tyrosine%20kinase%20inhibitors%20in%20epidermal%20growth%20factor%20receptor%20-mutant%20non-small%20cell%20lung%20cancer&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Tan,%20Chee-Seng&rft.date=2016-03-01&rft.volume=93&rft.spage=59&rft.epage=68&rft.pages=59-68&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2016.01.003&rft_dat=%3Cproquest_cross%3E1767623102%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1767623102&rft_id=info:pmid/26898616&rft_els_id=1_s2_0_S0169500216300034&rfr_iscdi=true |